Dolovet (Ketoprofen) is a non-steroidal anti-inflammatory drug (NSAID) primarily used in situations involving certain distressing symptoms by addressing pain, symptoms related to inflammatory or irritative states, and fever in livestock. Its applications span multiple therapeutic domains in veterinary medicine.

Key Therapeutic Applications

The medication is commonly used across conditions presenting with conditions characterized by periods of heightened symptoms and symptoms that create noticeable physiological strain, particularly those affecting the musculoskeletal system (such as lameness and arthritis), those associated with systemic imbalance (like pyrexia accompanying respiratory infections), and those related to periparturient comfort (such as acute clinical mastitis and post-operative pain management). It is applied across domains where additional symptomatic support is needed.

Quick Fact: Support for Key Symptom Clusters
Primary Focus	Applied in addressing pain, inflammation, and fever.
Benefit Framing	Assists in managing the overall symptom burden.
Target Context	Conditions marked by acute or disruptive episodes (e.g., post-operative, febrile, or locomotor strain).

Regulatory References

1. UK VMD regulatory document

Dolovet (Ketoprofen) is a veterinary medicinal product with eligibility strictly defined by regulatory standards concerning target species, age, and pre-existing health status.

The product is contraindicated and must not be used in animals with known hypersensitivity to Ketoprofen or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Absolute prohibitions apply to animals presenting with evidence of gastrointestinal ulceration or bleeding, blood dyscrasia (clotting disorders), or severe disease affecting the cardiac, hepatic, or renal systems.

Use is regulated based on the animal's age and physiological state. The medicine is not recommended for very young animals, including foals under 15 days of age or calves less than two months of age. Furthermore, use must be avoided in dehydrated, hypovolaemic, or hypotensive animals due to the potential for increased organ toxicity. Regulatory restrictions also apply to specific reproductive populations: the product is not for use in pregnant mares and certain classes of lactating dairy cattle.

The official interaction profile for Dolovet (Ketoprofen) is defined by its potential for additive adverse effects and alterations to the clearance of co-administered medicines, as documented in government regulatory sources.

Documented Interaction Restrictions

Restriction Type	Interacting Agent or Class	Outcome Described in Regulatory Labels
Contraindicated	Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Risk of additive gastrointestinal and renal toxicity. Must not be administered concurrently or within 24 hours of Dolovet.
High-Risk Interaction	Glucocorticosteroids	Documented increased risk of gastrointestinal ulceration and hemorrhage.
High-Risk Interaction	Anticoagulants (e.g., Coumarin-type)	Documented increased risk of bleeding due to pharmacodynamic interference with hemostasis.

Exposure-Altering and Pharmacodynamic Effects

The regulatory label identifies interactions that may alter the concentration or effect of other medicines:

• Diuretics and Nephrotoxic Drugs: Co-administration may result in reduced diuretic efficacy due to prostaglandin inhibition, alongside an increased, officially noted risk of renal toxicity.
• Lithium, Digoxin, and Methotrexate: Dolovet may increase the plasma concentrations of these agents by reducing their renal clearance, leading to elevated exposure. This effect is particularly significant with high-dose Methotrexate.

Specific cautions are noted for recipients who are dehydrated, hypovolaemic, or hypotensive, as these conditions may increase the risk of renal toxicity when Dolovet interacts with agents such as diuretics. No specific, formal interaction is documented in the veterinary product label concerning food, alcohol, or common herbal supplements.

Targeting the Eicosanoid Pathway: Enzyme Inhibition

The pharmacological activity of Ketoprofen involves the modulation of the eicosanoid pathway. Ketoprofen acts within the mechanistic domain of enzyme inhibition by targeting both the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This non-selective, reversible blockade reduces the synthesis of Prostaglandins and other lipid mediators derived from the Arachidonic Acid Cascade.

Mechanistic Cascade: Nociceptive Signal Transduction and Thermoregulation

The resulting deficit in Prostaglandins modulates the physiological processes responsible for nociceptive signal transduction and central thermoregulation. This mechanism decreases the sensitization of peripheral nociceptors and affects the central signaling in the hypothalamus, where PGE2 is crucial for adjusting the body's core temperature set-point.

️ Resulting Physiological Effects and Limitations

This mechanistic cascade results in the modulation of exaggerated physiological responses. However, the mechanism's non-selective nature inherently leads to reduced production of homeostatic Prostaglandins that regulate functions in systems like the gastrointestinal tract.

Dolovet is a non-steroidal anti-inflammatory drug (NSAID) whose administration parameters vary significantly across target species and the specific formulation used. The medicine is primarily presented as a Solution for Injection (100 mg/mL) and, in some regions, as an Oral Powder or bolus. Routes of administration include Intravenous (IV), Deep Intramuscular (IM), and Subcutaneous (SC) injection, depending on the species and context of use.

---

Dosing Principles

Dosing is determined by body weight, requiring precise calculation. Cattle and swine receive a standard dosage of 3 mg/kg body weight, while horses are administered 2.2 mg/kg. The frequency pattern for multi-day courses is typically once daily.

---

Course Duration and Procedural Constraints

Usage duration is specific to the target species. For cattle, the injectable course is utilized for up to 3 consecutive days. In horses, the course may extend up to 5 consecutive days for certain conditions, but treatment for acute episodes often involves a single injection. Usage protocols specify that the injection is administered with a high degree of dosing accuracy. Care is taken to avoid intra-arterial injection. Furthermore, administration to very young (less than 6 weeks) or aged recipients may necessitate management and possible dose adjustment.

Research Evidence / Overview of Studies for Dolovet (Ketoprofen)

The available research evidence for the active ingredient Ketoprofen comes primarily from controlled clinical trials and field studies. This summary describes the landscape of that evidence, focusing on the types of studies conducted and what their findings indicate, without offering any clinical advice or interpretation.

---

Evidence for Use in Musculoskeletal Pain and Inflammation

Research has examined the use of Ketoprofen in conditions associated with acute or disruptive episodes and functional limitations related to the musculoskeletal system. This evidence is largely derived from short-term randomized controlled studies that monitored outcomes related to physical discomfort.

Findings describe patterns observed in the studies where certain functional scores related to movement were observed to evolve during the defined study period. However, these studies primarily explored short-term symptom changes over periods of just a few days. Long-term effects are not fully established, and there is limited detailed information from large-scale studies on continuous use.

---

Evidence for Use in Febrile and Systemic Inflammatory States

Ketoprofen was evaluated in settings involving outcomes related to systemic imbalance and fever, often accompanying respiratory conditions. These trials monitored outcomes related to fever by assessing changes in rectal temperature and physiological strain. The findings indicate that research highlights changes measured during the study period, showing patterns related to changes in rectal temperature in febrile animals.

A key limitation is that some of the evidence is derived from highly controlled experimental models, which may not fully reflect the real-world conditions of naturally occurring infections. Consequently, certainty remains low regarding the full range of outcomes in the field.

---

Research Gaps and Areas of Uncertainty

While research contributes to the broader evidence landscape, several key areas remain uncertain. Evidence quality varies across studies, particularly between controlled laboratory settings and real-world field trials. Subgroup findings are uncertain, as the populations studied are often narrow, and data for certain groups remain insufficient. The limitations mean that findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. SPC for Ketoprofen 100 mg/ml Solution for Injection (Veterinary)
2. Analgesic efficacy of non-steroidal anti-inflammatory drugs in horses with colic: A systematic review.

Common questions about Dolovet (FAQ)

---

Q: What kind of pain or inflammation is Dolovet typically used to treat?

A: The active ingredient in Dolovet, Ketoprofen, is a Non-Steroidal Anti-Inflammatory Drug (NSAID) used to relieve pain and inflammation. Official product information indicates that its use includes the relief of pain and inflammation associated with conditions such as arthritis, musculoskeletal discomfort, menstrual pain, and post-operative discomfort.

Q: How long does the pain-relieving effect of a single dose of Dolovet usually last?

A: The duration of effect can vary based on individual factors and the formulation used. Studies on the active ingredient indicate that the plasma concentrations (drug levels in the blood) generally peak within one to two hours after administration. The elimination half-life of Ketoprofen is approximately 2 to 2.5 hours.

Q: Are there different formulations of Dolovet, such as tablets, drops, or topical applications?

A: Official documents for Dolovet mention an injection solution and an oral powder. The active ingredient, Ketoprofen, is also available in different formulations depending on the brand and region, which can include oral capsules, tablets, and topical gels.

Q: Can taking Dolovet for a long time increase the risk of side effects?

A: Regulatory documents state that the risk of serious side effects may increase with prolonged use of NSAIDs. This includes potential harm to the gastrointestinal tract and the cardiovascular system. Regulatory documents emphasize the importance of using the lowest effective dose for the shortest duration necessary, reflecting the potential for increased risk over time.

Q: Is it safe to consume alcohol while taking Dolovet?

A: Official labeling indicates that caution is advised regarding alcohol consumption. Since the active ingredient can cause stomach irritation, consuming alcohol at the same time may increase the risk of stomach bleeding. Additionally, alcohol could potentially increase side effects like dizziness or drowsiness.

Q: Is Dolovet recommended for pregnant or breastfeeding individuals?

A: Official regulatory warnings advise against using the active ingredient during pregnancy, especially after the last few weeks, as it poses a potential risk to the unborn baby. Use during breastfeeding requires consideration of potential risks, as outlined in the official warnings.

Q: Does Dolovet have an effect on blood clotting?

A: Yes, as an NSAID, the active ingredient in Dolovet has an effect on the body's clotting mechanisms. It reduces the ability of blood to clot. Official warnings indicate the risk of bleeding may be increased, particularly when co-administered with other medications that affect clotting.

Q: Is Dolovet a fast-acting medication, or does it take time to feel the full effects?

A: For immediate-release forms of the active ingredient, the onset of action for pain relief is relatively quick. Studies show that peak concentrations, which correlate with the strongest effect, are generally reached within one to two hours after administration.

Q: Is it normal to feel a bit dizzy or sleepy after taking Dolovet?

A: Official product information for the active ingredient lists dizziness and drowsiness (somnolence) as documented side effects. If these effects persist or become bothersome, consulting a healthcare professional is appropriate.

Q: Are skin rashes a possible side effect of using Dolovet?

A: Yes, skin rashes and other forms of hypersensitivity reactions are possible side effects. Official warnings also note that in rare cases, severe skin reactions may occur, including those triggered by sunlight (photosensitivity).

Q: What information should I share with my doctor before starting Dolovet?

A: Regulatory documents emphasize the importance of discussing your complete medical history. This should include any history of heart disease, high blood pressure, stomach ulcers or bleeding, kidney or liver problems, asthma, and a full list of all medications and supplements currently in use.

Q: What should I do if I forget to take a dose of Dolovet?

A: The general guidance found in patient information leaflets states that if a dose is missed, it should typically be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped to avoid taking two doses at once. Specific instructions are provided to avoid doubling the dose.

Q: Can Dolovet affect my ability to drive or operate machinery?

A: Caution is advised in official labeling. Because the active ingredient may cause side effects such as dizziness, drowsiness, or visual disturbances, if you experience these effects, it is advised to exercise caution with activities such as driving or operating machinery.

Q: How is Dolovet processed and eliminated by the body?

A: The active ingredient, Ketoprofen, is processed and broken down primarily by the liver. It is then largely eliminated from the body via the urine. This metabolism and elimination pathway is important to consider, especially in individuals with existing liver or kidney issues.

Q: Are there any long-term studies available on the safety of Dolovet?

A: While the active ingredient has been researched, regulatory documents highlight that the cardiovascular and gastrointestinal risks associated with NSAIDs tend to increase with the duration of use. This underscores the importance of ongoing medical monitoring during extended treatment.

Q: Does the time of day matter when taking Dolovet?

A: Official information for oral forms suggests that taking the medication with food or milk is generally advised to help minimize potential stomach upset. The time of day might be chosen based on when your pain is typically worst, to align with the medication's peak effect.

Q: Can Dolovet be taken on an empty stomach?

A: Taking the medication with food or milk is generally recommended to reduce the chance of stomach irritation. While taking it on an empty stomach may lead to faster peak absorption, it may increase the potential for digestive side effects.

Q: Does Dolovet require a prescription, or is it available over the counter?

A: The active ingredient, Ketoprofen, is available in various strengths and formulations. In many regions, lower-dose versions are available over-the-counter (OTC), while higher or injectable strengths typically require a prescription.

Q: Is there a risk of developing a dependency on Dolovet?

A: No, the active ingredient in Dolovet is a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not classified as a controlled substance. Therefore, it is not associated with the risk of physical dependence or addiction.

Q: What is the difference in effect between the immediate-release and extended-release forms of Dolovet (if applicable)?

A: According to official product labeling, immediate-release forms are designed for treating acute pain or sudden flare-ups, providing a quicker onset of effect. Extended-release forms are generally intended to manage the long-term, continuous signs and symptoms of chronic conditions, such as arthritis.

Q: Do other medications need to be stopped when starting a course of Dolovet?

A: Official warnings indicate that certain medications should not be used concurrently with Dolovet due to the risk of severe interactions. This includes other NSAIDs, corticosteroids (steroids), and blood thinners (anticoagulants). A healthcare professional must review your current medications to determine if any need to be paused or adjusted.

Q: Is it normal to have mild headaches when first starting Dolovet?

A: Yes, headache is listed in the official safety documents as a commonly reported side effect associated with the active ingredient. If the headache is severe or does not go away, consulting a healthcare professional is appropriate.

Q: Can Dolovet cause ringing in the ears (tinnitus)?

A: Tinnitus, which is a ringing or buzzing sensation in the ears, is documented in the official safety profile as a less common side effect associated with the active ingredient.

Q: What kind of monitoring (like blood tests) is sometimes needed while on Dolovet?

A: Due to the potential for the active ingredient to affect the kidneys and liver, regulatory documents indicate that regular medical monitoring, such as blood tests to check kidney and liver function, may be necessary during extended use.

Q: Are there specific symptoms that signal I should stop taking Dolovet immediately?

A: Official product information highlights that emergency medical attention is warranted if certain serious symptoms occur. These include signs of gastrointestinal bleeding (e.g., black, tarry stools or vomiting blood), severe allergic reactions, or symptoms suggestive of a heart attack or stroke.

How to Store and Dispose of Dolovet

Official regulatory documents define strict mandatory conditions for the storage and disposal of Dolovet (Ketoprofen).

---

Storage Requirements

• Temperature and Handling: Do not store the product above 25 C. It is explicitly required that the product must not be refrigerated or frozen.
• Protection and Packaging: The container must be stored in the outer carton in order to protect from light.
• Stability: Once the immediate container is first opened, any remaining product must be discarded after 28 days.
• Safety: The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired product must be in accordance with local requirements. Regulatory guidelines state that the medicine should not be disposed of via wastewater and recommend utilizing national take-back schemes.